ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio


LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer™.

See the rest here:
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Related Posts